Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

[1]  A. Berchuck,et al.  Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma , 2019, World Journal of Surgical Oncology.

[2]  Jae-Weon Kim,et al.  Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Putter,et al.  Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy , 2018, British Journal of Cancer.

[4]  T. Bosse,et al.  Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. , 2018, Gynecologic oncology.

[5]  Jacques Ferlay,et al.  International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. , 2018, Journal of the National Cancer Institute.

[6]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.

[7]  Begoña Díaz de la Noval,et al.  Lymphovascular Space Invasion for Endometrial Cancer: Undertreatment and Overtreatment Risks , 2017, International Journal of Gynecologic Cancer.

[8]  K. Pavlakis,et al.  Identifiable Risk Factors for Lymph Node Metastases in Grade 1 Endometrial Carcinoma , 2017, International Journal of Gynecologic Cancer.

[9]  K. Matsuo,et al.  Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer , 2015, Journal of surgical oncology.

[10]  T. Bosse,et al.  Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.

[11]  M. Munsell,et al.  Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[12]  L. V. van de Poll-Franse,et al.  Lymphovascular Space Invasion and the Treatment of Stage I Endometrioid Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[13]  B. Weigelt,et al.  Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.

[14]  L. Selvaggi,et al.  The impact of lymph vascular space invasion on recurrence and survival in patients with early stage endometrial cancer. , 2014, European journal of cancer care.

[15]  A. Mariani,et al.  Patterns of Recurrence in Stage I Endometrioid Endometrial Adenocarcinoma With Lymphovascular Space Invasion , 2013, International Journal of Gynecologic Cancer.

[16]  W. Feng,et al.  Clinicopathological Risk Factors for Pelvic Lymph Node Metastasis in Clinical Early-Stage Endometrioid Endometrial Adenocarcinoma , 2012, International Journal of Gynecologic Cancer.

[17]  P. Goodfellow,et al.  Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. , 2012, Gynecologic oncology.

[18]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[19]  A. Gadducci,et al.  Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. , 2009, Anticancer research.

[20]  T. Lesnick,et al.  Predictors of vaginal relapse in stage I endometrial cancer. , 2005, Gynecologic oncology.

[21]  H. Boezen,et al.  Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. , 2005, Gynecologic oncology.

[22]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[23]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[24]  R. Kurman,et al.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study , 1991 .

[25]  J. van Nagell,et al.  The prognostic significance of lymph‐vascular space invasion in stage I endometrial cancer , 1985, Cancer.

[26]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[27]  V. Abeler,et al.  Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.